Cargando…
Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis
PURPOSE: This meta-analysis aimed to assess the efficacy and safety of cyclin-dependent kinase (CDK) 4/6 inhibitors plus endocrine therapy (ET) in hormonal receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). METHODS: We searched PubMed, Em...
Autores principales: | Zheng, Jiani, Wu, Jingxun, Wang, Chunyue, Zhuang, Shiwen, Chen, Jianbo, Ye, Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272037/ https://www.ncbi.nlm.nih.gov/pubmed/32497134 http://dx.doi.org/10.1371/journal.pone.0233571 |
Ejemplares similares
-
Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies
por: Robertson, John F. R., et al.
Publicado: (2021) -
Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
por: Shen, Le-Sang, et al.
Publicado: (2020) -
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
por: Migliaccio, Ilenia, et al.
Publicado: (2015) -
Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity
por: Zhang, Jiaqiang, et al.
Publicado: (2021) -
Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
por: Alataki, Anastasia, et al.
Publicado: (2022)